Global Ureter Cancer Treatment Market, By Treatment (Ureterectomy, Chemotherapy, Radiation, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Ureter Cancer Treatment Market Analysis and Size
The global ureter cancer treatment market is expected to witness significant growth during the forecast period. Increasing cases of ureter cancer in leading economies worldwide is the crucial growth driver for the ureter cancer treatment market. Furthermore, the rising aging population prone to ureter cancer could boost the growth in the ureter cancer treatment market, in the coming years. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global ureter cancer treatment market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Ureter Cancer Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Ureterectomy, Chemotherapy, Radiation, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (Ireland), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Ureter cancer treatment is also known as renal pelvis, that is characterized by abnormal growth of abnormal cells that line the inside of the tubes. This type of cancer generally affects men above the age of 65 years and more. Chronic irritation in the kidney has been recognised as one of the main causes of ureter cancer. Some of the factors causing the irritation includes continuous smoking and analgesic nephropathy.
Global Ureter Cancer Treatment Market Dynamics
Drivers
- Increased Incidence of Ureter Cancer
Ureter cancer is a malignant neoplasm arising from urothelium. The disease is the ninth most common malignancy in the world, with around 2.5 million patients and 420,000 newly diagnosed cases every year. Bladder transitional cell carcinoma (TCC) accounted for around 90% of all urinary cancer cases.Thus, it boosts the market growth.
- Adoption of Multiple Growth Strategies
The global ureter cancer treatment market is competitive, with the presence of many well-established players. Many of these market players could adopt several growth strategies such as novel product launches, to remain competitive in the overall market. For instance, in 2019, Pfizer received the approval from the FDA for the drug BAVENCIO Plus Inylta, which has proven to be beneficial in treating patients in the last few years.
Opportunities
- Increased Government Funds
The ureter cancer treatment market players will seek investments from governments and private investors, which could help them in their long-term growth. These players could organize the funding in research and development activities to produce improved quality of products, which would meet the requirements of huge customers and help increase their consumer base.Thus, all these factors enhance the market expansion.
- Rise in Elderly Population
The rising global elderly population is a main factor boosting the market growth. As per the World Health Organization, the population of people aged over 60 years is projected to be 1.4 billion in 2020. Furthermore, in 2050, this number is anticipated to reach 2.1 billion. This factor is expected to create opportunities in the forecast period.
- Greater Adoption of Immunotherapy
The rising potential of immunotherapies to be used in adjuvant and neoadjuvant settings is now the primary subject of several clinical trials. These treatments will be combined with standard therapies to provide patients with safer and more effective treatment options. Innovative treatments such as CAR-T therapies and viral therapy continue to produce interest as a potential treatment of ureter cancer.
Restraints/Challenges
- Side Effects of Ureter Cancer Drugs
The side effects associated with these ureter cancer drugs could limit the growth of the global ureter cancer market over a forecast period. Effects such as loss of appetite, fever, rashes, fatigue, constipation, bleeding can hamper the market growth.
- Lack of Skilled Professionals
The lack of healthcare professionals who are unable to diagnose the condition and treat the same can hamper the market growth. Trained professionals are required for faster identification of the disease and immediate treatment process so that the recovery can be faster.
This global ureter cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global ureter cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In April 2022, Pfizer made an equity investment in Zentalis Pharmaceuticals, Inc. worth USD 25 million. This investment is anticipated to benefit Pfizer to leverage its development capabilities worldwide.
- In May 2022, Pfizer made a research collaboration agreement with NetVation DL Medicine for two years. This collaboration is predicted to assist and advance Pfizer in its research activities.
- In June 2022, Roche launched a human papillomavirus (HPV) self-sampling solution that allows patients to perform HPV screening in the presence of a healthcare worker. This is anticipated to expand the company’s cancer screening solution line-up.
Global Ureter Cancer Treatment Market Scope
The global ureter cancer treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Ureterectomy
- Chemotherapy
- Radiation
- Others
Route of Administration
- Oral
- Parenteral
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Ureter Cancer Treatment Market Regional Analysis/Insights
The global ureter cancer treatment market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global ureter cancer treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing the highest ureter cancer treatment market growth throughout the forecasted period due to the increased government initiatives and developing healthcare facilities.
North America dominates the market due to the rise cases of ureter cancer and increase in awareness about the ureter cancer treatment as well as advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Ureter Cancer Treatment Market Share Analysis
The global ureter cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global ureter cancer treatment market.
Key players operating in the global ureter cancer treatment market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Allergan,Inc (Ireland)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Fresenius SE & Co. KGaA (Germany)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
SKU-